AbCellera Finds Antibody Candidates Other Technologies Might Not

 
• By Joseph Haas

Emerging Company Profile: A platform research company, AbCellera is not developing any drugs, but has seen triple-digit revenue growth each year since 2015 via a model of discovering next-generation therapeutic antibody candidates for partners.

Emerging Company Profile Regular column feature image Version 2

More from R&D

More from Scrip